MDLinx August 1, 2024
Key Takeaways
Liraglutide may protect the brains of people with mild Alzheimer’s disease (AD), according to a new study.
Patients prescribed the glucagon-like peptide-1 (GLP-1) agonist had as much as an 18% slower decline in their cognitive function vs those on placebo.
The drug achieved this by slowing brain shrinking in areas responsible for a number of functions often altered by AD.
Liraglutide—a once-daily, injectable GLP-1 drug for obesity and diabetes—may protect the brains of people with mild Alzheimer’s disease (AD), according to a mid-stage study presented in July 2024 at the Alzheimer’s Association International Conference (AAIC) in Philadelphia.[1]
After 1 year of treatment, patients...
Today's Sponsors
Today's Sponsor